Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.99Last Year’s EPS
0.37Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -30.66%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The call reflects a highly positive performance with record-breaking revenue growth, successful ELEVIDYS launch, and strong guidance for 2025. Although there are challenges related to insurance and manufacturing, the overall outlook remains robust due to strategic advancements and pipeline progress.Company Guidance
During Sarepta Therapeutics' fourth quarter and full year 2024 financial results conference call, the company provided optimistic guidance for 2025, projecting net product revenue between $2.9 billion and $3.1 billion. This represents a 70% year-over-year growth, with ELEVIDYS expected to contribute over two-thirds of the revenue, reflecting a growth rate of over 160%. The call highlighted the success of ELEVIDYS, which achieved fourth-quarter sales of $384 million, marking a 112% increase over the previous sequential quarter, and surpassed $1 billion in sales since its initial approval in 2023. Sarepta also noted their expectation to achieve over $16 billion in cumulative operating income and over $13 billion in free cash flow by the end of 2030. The company is making strides in its LGMD franchise, anticipating three potential approvals in the next three years, and plans to transition to suspension manufacturing to improve cost of goods sold.Record-Breaking Revenue Growth
For the fourth quarter, net product revenue was $638 million, growing at 75% over the same quarter prior year. Full year net product revenue stood at $1.8 billion, representing year-over-year growth of 56%.
ELEVIDYS Gene Therapy Success
ELEVIDYS sales stood at $384 million in Q4, representing a 112% increase over the prior sequential quarter. Achieved over $1 billion in sales since initial approval, representing less than 5% of the on-label addressable opportunity.
Profitability and Cash Flow
Sarepta became sustainably profitable and cash flow positive in 2024.
Strong Guidance for 2025
2025 net product revenue guidance is between $2.9 billion and $3.1 billion, representing a year-over-year growth of 70%.
Pipeline Advancements
Significant progress with LGMD franchise, including potential approvals over the next three years. Closed the Arrowhead transaction, adding siRNA programs to the pipeline.
---
SRPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SRPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $106.86 | $103.06 | -3.56% |
| Nov 06, 2024 | $127.97 | $120.42 | -5.90% |
| Aug 07, 2024 | $140.06 | $136.40 | -2.61% |
| May 01, 2024 | $130.90 | $130.63 | -0.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sarepta Therapeutics (SRPT) report earnings?
Sarepta Therapeutics (SRPT) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Sarepta Therapeutics (SRPT) earnings time?
Sarepta Therapeutics (SRPT) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRPT EPS forecast?
SRPT EPS forecast for the fiscal quarter 2025 (Q1) is 1.99.
---
